Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion InfusionsDHA:ORIONINFU +0.10%81 EV-to-FCF is 94.14 as of Jul. 15, 2026, which is 62% above its 10-year median of 58.10. GuruFocus rates DHA:ORIONINFU with a GF Score™ of 81/100 and a GF Value™ of BDT316.17 (Fairly Valued). The stock has 3 warning signs investors should review. Among 564 Drug Manufacturers companies, Orion Infusions ranks worse than 85.28% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Orion Infusions's Enterprise Value is BDT6,210.9 Mil.
Orion Infusions's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was BDT66.0 Mil. Therefore, Orion Infusions's EV-to-FCF for today is 94.14.
The historical rank and industry rank for Orion Infusions's EV-to-FCF or its related term are showing as below:
DHA:ORIONINFU'
s EV-to-FCF Range Over the Past 10 Years
Min: -1769.16 Med: 58.1 Max: 4860.96
Current: 96.11
During the past 13 years, the highest EV-to-FCF of Orion Infusions was 4860.96. The lowest was -1769.16. And the median was 58.10.
DHA:ORIONINFU's EV-to-FCF is ranked worse than 85.28% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.895
vs DHA:ORIONINFU: 96.11
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Orion Infusions's PE Ratio (TTM) for today is calculated as:
Orion Infusions's share price for today is BDT291.20.
Orion Infusions's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT1.740.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Orion Infusions EV-to-FCF Related Terms
Orion Infusions EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Orion Infusions's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONINFU vs ZTS, UTHR, VTRS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Infusions EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Orion Infusions's EV-to-FCF falls into.
Orion Infusions's current Enterprise Value is BDT6,210.9 Mil.
Orion Infusions's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT66.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Infusions (DHA:ORIONINFU) has a EV-to-FCF of 94.14 as of Jul. 15, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Orion Infusions and its competitors. This is 62% above median its historical median of 58.10. According to the industry distribution chart, Orion Infusions ranks #481 out of 564 companies in the Drug Manufacturers industry, placing it in the top 85.3%.
Is Orion Infusions' EV-to-FCF too high?
Orion Infusions' current EV-to-FCF of 94.14 is 62% above median its 10-year median of 58.10. The Drug Manufacturers industry median EV-to-FCF is 20.90. Orion Infusions' value of 94.14 is 350.5% above this industry median. Based on the distribution chart, Orion Infusions ranks #481 out of 564 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Orion Infusions has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orion Infusions ranks #481 out of 564 companies for EV-to-FCF. This places Orion Infusions in the lower half of its industry. The industry median EV-to-FCF is 20.90. Orion Infusions' value of 94.14 is 350.5% above this benchmark. While the company's 10-year median is 58.10 vs. the industry median of 20.90, Orion Infusions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.90, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Infusions's current EV-to-FCF of 94.14 is 350.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Orion Infusions and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Infusions's current EV-to-FCF is 94.14, which is 62% above median its own 10-year median of 58.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Fairly Valued. The stock's GF Value™ is BDT316.17, compared to a current price of BDT291.20 — trading 7.9% below its estimated fair value. The current EV-to-FCF is 94.14, which is 62% above median its 10-year median of 58.10 and 350.5% above the Drug Manufacturers industry median of 20.90. Orion Infusions' overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current EV-to-FCF is 94.14 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued.
The current stock price of BDT291.20 is trading 7.9% below its estimated GF Value™ of BDT316.17.
GuruFocus considers Orion Infusions to be Fairly Valued.
Key valuation signals for DHA:ORIONINFU:
EV-to-FCF: 94.14 (62% above median its 10-year median of 58.10)
GF Value™: BDT316.17 vs. price of BDT291.20 (7.9% below fair value)
Industry Position: 350.5% above the Drug Manufacturers median (#481 of 564)
No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
81GF Score
Get the complete analysis for DHA:ORIONINFU
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONINFU has been successfully added to your 
